Advertisement

Surgery Today

, Volume 49, Issue 1, pp 90–95 | Cite as

Meaning of C-reactive protein around esophagectomy for cStage III esophageal cancer

  • Yasunori OtowaEmail author
  • Tetsu Nakamura
  • Yuta Yamazaki
  • Gosuke Takiguchi
  • Akio Nakagawa
  • Masashi Yamamoto
  • Shingo Kanaji
  • Takeru Matsuda
  • Taro Oshikiri
  • Satoshi Suzuki
  • Yoshihiro Kakeji
Original Article

Abstract

Purpose

The prognosis of esophageal cancer is dismal, and the 3-year overall survival of cStage III does not reach 50.0%. C-reactive protein (CRP) is a well-known protein that reflects the short- and long-term operative outcomes of esophageal cancer. However, since elevated CRP levels are often observed in cStage III esophageal cancer, whether or not CRP still reflects the prognosis is unclear.

Methods

Eighty-four patients who were diagnosed with cStage III esophageal cancer and underwent R0/1 operation from January 2007 to December 2014 were retrospectively evaluated.

Results

The mean age was 66.8 years, and the majority of patients were male. The median preoperative and postoperative CRP levels were 0.15 and 1.47 mg/dl, respectively. A majority of the patients underwent thoracoscopic surgery, and the median blood loss and operation duration were 456 ml and 11.6 h, respectively. Forty-six patients (54.8%) died during the observation period, and the 3-year overall survival was 52.4%. A multivariate analysis showed that the preoperative CRP level, postoperative albumin level, blood loss, and complications were independent prognostic factors. A multiple linear regression analysis showed that an elevated postoperative CRP level was affected by the operation duration and preoperative CRP levels.

Conclusions

These findings suggest that the preoperative CRP level is a prognostic factor for cStage III esophageal cancer and that postoperative elevation in the CRP level is affected by the operation duration.

Keywords

C-reactive protein Esophageal cancer Surgical stress 

Notes

Acknowledgements

We thank Saki Fujimoto for helping us collect the data.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.Google Scholar
  2. 2.
    Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. The Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan. Esophagus. 2017;14:189–214.CrossRefGoogle Scholar
  3. 3.
    Okamura A, Takeuchi H, Matsuda S, Ogura M, Miyasho T, Nakamura R, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:3130–35.CrossRefGoogle Scholar
  4. 4.
    Tsujimoto H, Takahata R, Nomura S, Kumano I, Matsumoto Y, Yoshida K, et al. Predictive value of pleural and serum interleukin-6 levels for pneumonia and hypo-oxygenations after esophagectomy. J Surg Res. 2013;182:e61-7.CrossRefGoogle Scholar
  5. 5.
    Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H. Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response. Jpn J Clin Oncol. 2006;36:632–7.CrossRefGoogle Scholar
  6. 6.
    Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Osada S, Takayama E, et al. Activation of monocytes and endothelial cells depends on the severity of surgical stress. World J Surg. 2000;24:10–6.CrossRefGoogle Scholar
  7. 7.
    Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg. 1999;177:78–82.CrossRefGoogle Scholar
  8. 8.
    Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRefGoogle Scholar
  9. 9.
    Otowa Y, Nakamura T, Yamamoto M, Kanaji S, Matsuda Y, Matsuda T, et al. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. Dis Esophagus. 2017;30:1–5.CrossRefGoogle Scholar
  10. 10.
    Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto J, Furukawa T, et al. Role of postoperative C-reactive protein levels in predicting prognosis after surgical treatment of esophageal cancer. World J Surg. 2017;41:1558–65.CrossRefGoogle Scholar
  11. 11.
    Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.CrossRefGoogle Scholar
  12. 12.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.CrossRefGoogle Scholar
  13. 13.
    Park JK, Kim JJ, Moon SW. C-reactive protein for the early prediction of anastomotic leak after esophagectomy in both neoadjuvant and non-adjuvant therapy case: a propensity score matching analysis. J Thorac Dis. 2017;9:3693–702.CrossRefGoogle Scholar
  14. 14.
    Kano K, Aoyama T, Nakajima T, Maezawa Y, Hayashi T, Yamada T, et al. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. BMC Cancer. 2017;17:812.CrossRefGoogle Scholar
  15. 15.
    Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.PubMedGoogle Scholar
  16. 16.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. Chichester: Wiley; 2009.Google Scholar
  17. 17.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefGoogle Scholar
  18. 18.
    Japanese Society for Esophageal Diseases. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: preface, general principles, part I. Esophagus. 2004;1:61–88.Google Scholar
  19. 19.
    Otowa Y, Nakamura T, Takiguchi G, Tomono A, Yamamoto M, Kanaji S, et al. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Dis Esophagus. 2016;29:146–51.CrossRefGoogle Scholar
  20. 20.
    Sato N, Endo S, Kimura Y, Ikeda K, Aoki K, Iwaya T, et al. Influence of a human protease inhibitor on surgical stress induced immunosuppression. Dig Surg. 2002;19:300–5.CrossRefGoogle Scholar
  21. 21.
    Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361–8.CrossRefGoogle Scholar
  22. 22.
    Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189:599–604.CrossRefGoogle Scholar
  23. 23.
    Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;z379:1887–92.CrossRefGoogle Scholar
  24. 24.
    Ahmadi N, Crnic A, Seely AJ, Sundaresan SR, Villeneuve PJ, Maziak DE, et al. Impact of surgical approach on perioperative and long-term outcomes following esophagectomy for esophageal cancer. Surg Endosc. 2018;32:1892–900.CrossRefGoogle Scholar
  25. 25.
    Kanekiyo S, Takeda S, Tsutsui M, Nishiyama M, Kitahara M, Shindo Y, et al. Low invasiveness of thoracoscopic esophagectomy in the prone position for esophageal cancer: a propensity score-matched comparison of operative approaches between thoracoscopic and open esophagectomy. Surg Endosc. 2018;32:1945–53.CrossRefGoogle Scholar
  26. 26.
    Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002;236:184–90.CrossRefGoogle Scholar
  27. 27.
    Engelman E, Maeyens C. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg. 2010;14:788–804.CrossRefGoogle Scholar
  28. 28.
    Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Yasunori Otowa
    • 1
    • 2
    Email author
  • Tetsu Nakamura
    • 2
  • Yuta Yamazaki
    • 2
  • Gosuke Takiguchi
    • 2
  • Akio Nakagawa
    • 2
  • Masashi Yamamoto
    • 2
  • Shingo Kanaji
    • 2
  • Takeru Matsuda
    • 2
  • Taro Oshikiri
    • 2
  • Satoshi Suzuki
    • 2
  • Yoshihiro Kakeji
    • 2
  1. 1.Department of SurgeryKita-Harima Medical CenterOnoJapan
  2. 2.Division of Gastrointestinal Surgery, Department of SurgeryKobe University Graduate School of MedicineKobeJapan

Personalised recommendations